Project Grant R21CA295428
Award Date 4/1/26
Completion Date 3/31/28
Dollars Obligated $432K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Bronx, NY 10461, USA
Similar Awards
- Federal Project Grant Award Summary Albert Einstein College of Medicine received a $442,816 Project Grant from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), awarded April 2, 2026, with completion targeted for March 31, 2027. This award funds research interrogating erythroid differentiation and the BCL-XL axis in TP53-mutated acute myeloid leukemia (AML). The project addresses a critical clinical gap by investigating how TP53-mutated AML patients...
- Federal Grant Award Summary Albert Einstein College of Medicine received a $692,197 Project Grant from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) for the period May 1, 2026 through April 30, 2031. The award funds research and development of MTAP (Methylthioadenosine Phosphorylase) transition state analog inhibitors designed to enable synthetic-lethal cancer therapy approaches. The project delivers novel, highly specific MTAP inhibitor compounds and...
- Federal Grant Award Summary Albert Einstein College of Medicine received a $680,121 Project Grant award from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396), effective April 1, 2026 through March 31, 2031. This award supports fundamental research to understand the immunoevasion mechanisms employed by precancerous stem cells in basal-like breast cancer (BLBC), with the goal of developing immunoprevention strategies to intercept progression to aggressive...
- Federal Project Grant Award Summary Albert Einstein College of Medicine received a $431,970 Project Grant award from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) effective April 1, 2026, through March 31, 2028. The award supports research to decipher mechanisms of resistance to anti-TROP2 (tumor-associated glycoprotein 2) antibody-drug conjugates, specifically sacituzumab govitecan (SG), which is currently approved for treating advanced...
- Federal Grant Award Summary Baylor College of Medicine received a $160,500 Project Grant award from the National Cancer Institute under the Cancer Biology Research program (CFDA 93.396), effective July 10, 2025, with completion targeted for June 30, 2027. The award funds the development and investigation of in vivo murine models to examine the role of caspase-2 in nucleophosmin-mutated acute myeloid leukemia (NPM1C+ AML). The research deliverables include the establishment of transgenic mouse...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded The Feinstein Institutes for Medical Research a $167,500 Project Grant under the Cancer Treatment Research program (CFDA 93.395) effective August 1, 2025, through July 31, 2027. This research initiative addresses chronic lymphocytic leukemia (CLL), the most prevalent adult leukemia in the United States, by investigating the cellular and molecular mechanisms underlying communication between cancer cells and...
- Federal Project Grant Award Summary The National Cancer Institute awarded $1,034,176 to Sloan-Kettering Institute for Cancer Research under the Cancer Biology Research program (CFDA 93.396) on August 18, 2025, for a project extending through July 31, 2032. The research focuses on understanding and targeting aberrant RNA splicing in leukemia, building on the principal investigator's 13-year track record of discovering genetic alterations in hematopoietic malignancies. The project aims to...
- Federal Grant Award Summary Western University of Health Sciences received a $429,000 Project Grant award from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) effective July 1, 2025, through June 30, 2028. The award funds the development and optimization of dual chimeric antigen receptor natural killer (CAR-NK) cells engineered to specifically target acute myeloid leukemia (AML) cells with human leukocyte antigen (HLA)-DR loss. The research...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded the Beckman Research Institute of the City of Hope a $517,090 Project Grant under the Cancer Biology Research program (CFDA 93.396) on August 18, 2025, to investigate the role and biological function of a novel signature gene designated AL021978.1 (A978) in Philadelphia chromosome (PH)-positive and PH-like B-cell acute lymphoblastic leukemia (B-ALL). The research aims to address high-risk leukemia subtypes with survival...
- Federal Grant Award Summary Thomas Jefferson University (Sidney Kimmel Medical College) received a $484,405 Project Grant award from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396), effective September 1, 2025 through August 31, 2030. The award funds fundamental research investigating how NSD2 (nuclear receptor binding SET domain protein 2) mutations drive acute lymphoblastic leukemia (ALL) transformation, with particular focus on relapsed B-cell ALL...